Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Geron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest actions by the Food and Drug Administration (FDA). After closing at $3.90 on Thursday, the stock surged by more than 20% to over $4.66, as we predicted in 2023.

Very good news for Geron stock price: now what?

Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients with a group of blood cancers.

Geron shares surge after U.S. FDA approves blood disorder drug

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not respon.

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness of Imetelstat in inhibiting telomerase and treating diseases. The FDA Oncologic Drugs Advisory Committee voted in favor of Imetelstat (12 to 2) for patients with MDS.

Geron Corporation: A High-Risk Deal With A Good Chance Of Success

Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.

Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024. “Since the FDA ODAC's 12 to 2 vote in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS in Mar.

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

ICL-Israel Chemicals

iQIYI

Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heightened volatility, translating into significant short-term gains for those adept at timing the market.

The Top 3 Penny Stocks to Buy in April 2024

Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetelstat 12 to 2 for patients with low-risk myelodysplastic syndrome. The European Commission has already accepted the MAA for review of imetelstat for low-risk myelodysplastic syndrome; European approval is possible in 2025.

Geron: FDA PDUFA Review With Continued Imetelstat Advancement

ADMA Biologics

Lyra Therapeutics

Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.

3 'Buy-Rated' Biotech Stocks Under $10

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A l.

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Neurocrine Biosciences

Viking Therapeutics

The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030.

3 Red-Hot Biotech Rockets Blasting Off in 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23rd Annual Needham Virtual Healthcare Conference Wednesday, April 10th at 10:15 a.m. ET (Fireside Chat) Stifel's 2024 Virtual Targeted Oncology Days Wednesday, April 17th at 11:30 a.m. ET (Corporate Presentation) A.

Geron to Participate at Upcoming Investor Conferences in April

Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering includ.

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jet.AI Inc

Verb Technology Company Inc

Navigating the realm of penny stocks can unlock pathways to significant financial growth, presenting a landscape ripe with opportunities for those astute enough to capitalize on them. Central to achieving success in this area is the diligent identification of sectors poised for exponential growth.

Choosing the Right Penny Stocks, 3 Hot Tips

Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited by a momentous announcement earlier in the day.

Can Geron Corporation maintain momentum following FDA's backing?

Geron Corp.'s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company's blood-disorder drug imetelstat and said its benefits outweigh the risks.

Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug

Geron (NASDAQ: GERN ) stock is rocketing higher on Friday following news that advisors to the Food and Drug Administration (FDA) are backing its blood disorder drug, imetelstat. According to a press release from late-stage clinical biopharmaceutical company, the Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of imetelstat.

Why Is Geron (GERN) Stock Up 94% Today?

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-in.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated risks in patients.

Geron's blood disorder drug gets FDA advisers' backing

The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the potential benefit, documents released ahead of a meeting of independent experts showed.

US FDA staff flags concerns about Geron's anemia treatment

Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $194 million in 2023, with $378.1 million in cash at the end of the year. Geron stock has risen by 12% since December, but faces potential risks from an upcoming FDA Advisory Committee meeting and competition from Bristol-Myers Squibb's Reblozyl.

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript February 28, 2024 8:00 AM ET

Geron Corporation (GERN) Q4 2023 Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023. “Geron's progress and execution throughout 2023 has paved the way for a potentially transformational 2024, as we plan for the transition to becoming a commercial compan.

News for Geron Stock (GERN)